



# Open Collaboration for Innovative DDS Technology Development

Are you ready to become the real  
pharmaceutical scientist?



This integrated research and training program has been established since 2020 and this time is our 5th batch program. This program will give a chance to the talented researcher and scientist in pharmaceutical and healthcare field from Universitas Indonesia to do the collaboration research and training program with Daewoong Group as one of the biggest global health care group from South Korea. Training and research program will conduct in both Indonesia and Korea, and this program is fully funded program.

JANUARY

29

Register Now!

**DFINDONESIA.VIVIDAPP.KR**

(Please check the detail requirement in the next poster)

For further inquiries please send us email to [df@daewoong.co.kr](mailto:df@daewoong.co.kr)

# REGISTRATION GUIDELINE



## ELIGIBILITY

- Currently an enrolled master/PhD student, researcher, or professor in Universitas Indonesia (junior researcher/asisten ahli/lecturer, doctor, and master students are preferred)
- Willing to do research related to the pharmaceutical product development
- No issue to travel abroad (some research period will be done in South Korea)
- Fluent in English for daily communication (able to speak in Korea can be an additional point)

## BENEFITS

- Fully funded program (Airline ticket, visa, accommodation, research fee, monthly stipend)
- Chance to do research with high technology pharmaceutical laboratory in South Korea (specially for junior researcher, master or doctoral students)
- Chance to make a patent or collaborative invention during research with Daewoong Group
- Able to claim credit (SKS) to your campus after the program is done


## REQUIRED DOCUMENTS

- Research proposal
- Certificate of enrollment / proof of active lecturer or researcher
- Personal CV




## REGISTRATION PROCESS

- Choose one research topics from the list
- Write your research proposal [download here : [bit.ly/dwresearchproposal](https://bit.ly/dwresearchproposal) ]
- Write your application form [download here : [bit.ly/dwapplicationform](https://bit.ly/dwapplicationform) ]
- Prepare your certificate of enrollment
- Upload all of your data above in [dfindonesia.vividapp.kr](https://dfindonesia.vividapp.kr)
- Please be aware that all document and video must be in English!
- During registration, **please register your team of research under one Senior Researcher** (lecturer or professor)



# RESEARCH TOPICS



## EXTENDED-RELEASE DOSAGE FORM (ER)

Code No.	Project Title	Active ingredient	Study period
ER-1	Development of Sustained Release Tab.	Nifedipine	3M
ER-2	Development of Dual Delayed Release System	Esomeprazole	3M
ER-3	Development of Gastroretentive Drug Delivery System	Epalrestat	6M
ER-4	Development of simple production process of the depot injectable with GLP-1 agonist (Liraglutide) delivery (W/O/W → O/W)	GLP-1 agonist SGLT-2	6M
ER-5	Development of injectable diluent technology for suppressing initial drug release of microsphere	-	6M
ER-6	Screening of excipients to improve local tolerance of the microcrystal suspension	Nicosamide	6M
ER-7	Liposome formulation lasting for more than 3 days (long acting injectable)	Ropivacaine	6M
ER-8	Depot formulation for the protein drug(Growth hormone) delivery	Insulin, hGH	6M
ER-9	Development of sustained-release tablet with improved side effects for AD treatment	Donepezil, Fexuprazan	6M

## SOLUBILIZATION AND FIXED DOSE COMBINATION (SFDC)



Code No.	Project Title	Active ingredient	Study period
SFDC-1	A formula of micro-tablets of the fixed-dose combination of Fexuprazan and Aspirin and the advanced manufacturing process	Fexuprazan Aspirin	6M
SFDC-2	Atorvastatin Solubilization	Atorvastatin	3M
SFDC-3	Nintedanib Solubilization	Nintedanib	3M
SFDC-4	Improving solubility and stability of anti-cancer drugs	Lenvatinib	6M
SFDC-5	Solubilization study by change the liquid composition to powder in the formulation change (soft to tablet)	Midostaurin	6M
SFDC-6	Securing a solubilization prescription that avoids patents limited to solubilizers	Edoxaban	6M
SFDC-7	Single-layer tablets to improve the stability of tablet formulations by minimizing DDI between active ingredients	Lafutidine Sucralfate Etc.	6M
SFDC-8	Improving stability of H2 blockers drug Oral solution: Composition research to ensure stability	Ranitidine Famotidine Etc.	6M



# RESEARCH TOPICS




## NEW ROUTE OF ADMINISTRATION (NRA)

Code No.	Project Title	Active ingredient	Study period
NRA-1	The development of Fexuprazan patch formula based on polyacrylate with improving compatibility and stability	Fexuprazan	6M
NRA-2	The development of highly loaded Bersiporocin patch formula(over 20% API) with reducing skin irritation and recrystallization	Bersiporocin	3M
NRA-3	Semaglutide Tablet : Enhanced absorption	Semaglutide	6M
NRA-4	Studying N2B delivery technology	Psychedelic Antiviral agent	6M
NRA-5	Intravitreal Implant for Ocular Drug Delivery Development of Intravitreal Implant Drug Delivery Platform using Novel Therapeutics and Drug Repurposing for Chronic Eye Disorders	JAK Inhibitor Steroid	TBD


## ANALYTICAL RESEARCH (AR)

Code No.	Project Title	Active ingredient	Study period
AR-1	Nitrosamines Risk Evaluation Study	Nitrosamines	6M
AR-2	Development of Multi-Vitamin Analysis Method	Vitamines	6M



## CELL AND GENE THERAPY (CGT)

Code No.	Project Title	Active ingredient	Study period
CGT-1	Development of scale-up process cartilage spheroids derived from DW-MSC	Pluripotent stem cell-derived mesenchymal stem cells	6M
CGT-2	Development of ultra-high sensitive purity markers for DW-MSC		6M
CGT-3	Development of MSC frozen formulation		6M
CGT-4	Analysis and evaluation of MSC characteristics using the disease animal model		12M




# RESEARCH TOPICS

## BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT (BPD)



Code No.	Project Title	Active ingredient	Study period
BPD-1	Development of lyophilized formulation of drug product: rhTGF- $\beta$ 3	rhTGF- $\beta$ 3	6M
BPD-2	A study on the cartilage regeneration mechanism of rhTGF- $\beta$ 3 : rhTGF- $\beta$ 3	rhTGF- $\beta$ 3	6M
BPD-3	Development of recombinant protein extraction method in Paste formulation	rhBMP-2	3M
BPD-4	Physicochemical characterization of protein-based pharmaceuticals for Sarcopenia therapy (molecular weight, primary structure, glycosylation analysis)	Fc fusion protein	6M



## TISSUE ENGINEERING AND REGENERATIVE MEDICINE (TERM)

Code No.	Project Title	Study period
TERM-1	Functional application technology in Resorbable adhesion barrier	6M
TERM-2	Safety of Crosslinking technology in hyaluronic acid	6M
TERM-3	Manufacturing technology in dissolvable Microneedle drug delivery	6M
TERM-4	Photopolymerized Bio-Ink Development for Patient Specific Surgical Guide	3M
TERM-5	Extrusion process parameter set build-up for polymer/BGS7 composite	3M
TERM-6	Complex artificial dermal replacement technology	6M

